行情

BPMX

BPMX

BIOPHARMX
AMEX

实时行情|Nasdaq Last Sale

0.5800
-0.1982
-25.47%
盘后: 0.5488 -0.0312 -5.38% 17:21 01/29 EST
开盘
0.6850
昨收
0.7782
最高
0.7100
最低
0.5000
成交量
469.90万
成交额
--
52周最高
4.463
52周最低
0.2580
市值
1.10亿
市盈率(TTM)
-0.4727
分时
5日
1月
3月
1年
5年

分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

BPMX 新闻

  • 鲍威尔讲话后 交易员加大对2020年美联储降息的押注
  • 新浪美股.2小时前
  • 美联储将在上半年调整回购操作的规模和定价
  • 新浪美股.2小时前
  • 尾盘:鲍威尔讲话后美股涨幅收窄 道指涨70点
  • 新浪美股.2小时前
  • 美联储略偏鸽派言论打压美元 黄金涨势较为平缓
  • 新浪财经-自媒体综合.2小时前

更多

所属板块

生物技术和医学研究
-0.30%
制药与医学研究
+0.09%

热门股票

名称
价格
涨跌幅

BPMX 简况

BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women's health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia. Its VI2OLET is an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort and is clinically demonstrated to alleviate the symptoms associated with FBC, including tenderness, aches and swelling. It is developing BPX02, which is an injectable utilizing biologic materials for aesthetic dermatology applications.
展开

Webull提供Biopharmx Corp的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。